According to the Drugs and Therapeutics Bulletin, Grazax - a new sublingual immunotherapy for grass allergies - is simply not cost effective.

Research shows that the benefits to patients are quite modest, while the cost is quite high. Grazax is on the market England and costs £67.50 (about $100) for a mere 30 tablets! However, most patients taking Grazax still have to use other allergy treatments, including antihistamines and steroid nasal sprays.

After stopping Grazax, the small benefits did persist for another season, but only if patients have taken Grazax for at least three years.

There are no studies that compare Grazax with other treatments. The most obvious comparison would be with subcutaneous immunotherapy or allergy shots.

Source: Nursing Times